Matching Geography

Reports matching your search in:
 
 

Research Assistance

 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!
 

Biomarkers

1594

A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Biomarkers can be valuable tools in clinical diagnostics as well as in therapeutic discovery and development. They can be used to predict response to therapy or risk of side effects for personalized medicine applications.
Additional types include predisposition, screening, diagnostic, prognostic, toxicity, pharmacodynamic, and other biomarkers.

The existence of living organisms or biological processes, a particular disease state, or a fragment of DNA sequence can indicate biomarkers. Locations of a particular molecule (cellular or subcellular, tissue or organ locations) can also be a biomarker.

Biomarkers ideal for diagnosis should have great sensitivity, specificity, and accuracy in reflecting total disease burden. A tumor marker should also be prognostic of outcome and predictive of tumor recurrence and effectiveness of anti-cancer treatments.

Biomarkers for screening purposes must be highly specific, minimizing false positive and negative results. The biomarker must be able to clearly reflect the early stage of disease and it must be easily detected without complicated medical procedures. The disease markers released to serum and urine are good targets for application of early screening. The method for screening should be cost effective. Biomarkers are commonly detected through blood, urine, other body fluids, and tissue samples.

Biomarkers play a major role in medicinal biology. Biomarkers bring the future things in our hand by helping in early diagnosis, disease prevention, drug target identification, drug response etc. Several disease-based biomarkers had been identified for many diseases such as serum LDL for cholesterol, blood pressure, P53 gene and MMPs for cancer. Gene based biomarkers are found to be effective and acceptable markers in the present scientific world.

RSS Feeds

All reports in Biomarkers

< prev 1  2  3  4  5  next >
Commercializing Biomarkers in Therapeutic and Diagnostic Applications
5/1/2012 | published by: CHI Insight Pharma Reports
... biomarkers and successfully commercialize them in therapeutic and diagnostic applications. Included in this publication: Biomarker definitions and guidelines for their development and validation Applications of biomarkers in oncology, cardiology, neurology, drug safety, and other areas ...  |  more...
$3,195.00
Biosensors - A Global Market Overview
3/13/2012 | published by: Industry Experts
... areas of drug discovery, biodefense, environmental monitoring, and narcotic detection. These technological developments portray a healthy trend for up-and-coming markets, while in the case of existing markets with a high proportion of application, biosensors would ...  |  more...
$4,050.00
World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)
3/1/2012 | published by: Kalorama Information
... the report profiles key competitors and discusses trends that are important for understanding this much-discussed growth area of the diagnostic industry. The concept of 'Personalized Medicine', as seen by Kalorama clinical diagnostics industry analyst Shara ...  |  more...
$3,795.00
Biomarkers Market Discovery Technologies (Proteomics, Genomics, Imaging, Bioinformatics), Applications (Drug Discovery, Personalized Medicine, Molecular Diagnostics) & Indications (Cancer, Cardiovascular & Neural) Global Trends & Forecasts (2011 - 2020)
2/2/2012 | published by: MarketsandMarkets
... based on different parameters such as on the basis of their application, their characteristics and on their usage in decision making in early drug development. With drug development facing challenges from ever increasing cost of ...  |  more...
$4,650.00
Companion Diagnostics and Biomarker Development
2/1/2012 | published by: Cutting Edge Information
... companion diagnostics (CDx) offer companies the ability to target a subset of patients for testing — unleashing the potential for greater efficacy, accelerated regulatory approval and better reimbursement. Companion diagnostics are not suitable for every ...  |  more...
$7,695.00
Biomarker Partnering Terms and Agreements, 3rd Edition
2/1/2012 | published by: CHI Insight Pharma Reports
... in biomarker partnering deals Deal terms analaysis Average biomarker deal values Biomarker partnering agreement structure Biomarker partnering contract documents Top biomarker deals by value Most active biomarker dealmakers The Biomarker Partnering Terms and Agreements report ...  |  more...
$2,695.00
Biomarker Partnering Terms and Agreements
2/1/2012 | published by: Current Partnering
... analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. ...  |  more...
$2,695.00
Conference Documentation: Biomarkers Summit
1/17/2012 | published by: SMI Publishing, Ltd
... 5th year, this event will present attendees with the latest developments in the field through case-studies and insights from industry leaders in biomarker discovery and development as well as acting as the perfect forum for ...  |  more...
$800.00
Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success
1/16/2012 | published by: GBI Research
... - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success” which provides an insight into the different endpoints that are used in cardiovascular clinical trials. ...  |  more...
$3,500.00
Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
10/3/2011 | published by: GBI Research
... - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly”, which provides key data, information and analysis of the major trends and issues affecting biomarkers in the drug discovery process. The ...  |  more...
$3,500.00
Recalibrating Goals Can Lead to Better Outcomes in Academic/Industry Biomarker and Diagnostics Collaborations
10/1/2011 | published by: Decision Resources
... of therapeutic areas, but some are much more common than others. Which therapeutic areas have the greatest number of biomarker/diagnostics collaborations? Industrial science and academic science have fundamentally different orientations, as well as different cultures ...  |  more...
$4,600.00
Cardiac Biomarkers
10/1/2011 | published by: Global Industry Analysts
... (CK-MB), Cardiac Troponin, & Myoglobin), and Congestive Heart Failure (CHF) Tests (BNP &NT-proBNP)). The report provides separate omprehensive analytics for the US, Europe, and Rest of the World. Annual estimates and forecasts are provided for ...  |  more...
$4,500.00
Freedonia Focus on Biochip Products & Services
9/30/2011 | published by: Freedonia Focus
... and application forecasts, industry composition and leading participants. Product segments cover biochip products (including biochips or microarrays, reagents and consumables, and other biochip products) and biochip services. Applications include drug discovery, life science research, in ...  |  more...
$600.00
Conference Documentation: Biomarkers in Clinical Trials
9/20/2011 | published by: SMI Publishing, Ltd
... safety have stimulated a need for personalized medicine; and to increase the predictability of clinical research to reduce development cost and time. The use of biomarkers in no longer limited to whether a patient will ...  |  more...
$800.00
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
9/1/2011 | published by: TriMark Publications
... types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as ...  |  more...
$3,400.00
Biomarker and Diagnostic Opportunities in Respiratory Diseases
9/1/2011 | published by: Decision Resources
... certainly present. Exploratory respiratory biomarkers are a part of the pharmaceutical and diagnostic R&D process in several different ways: they help determine treatment choice, monitor disease activity, aid in making differential diagnoses, and stratify patients ...  |  more...
$4,600.00
Companion Diagnostics: World Market Outlook
8/22/2011 | published by: Visiongain
... the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict ...  |  more...
$2,331.00
Biomarkers
8/1/2011 | published by: Global Industry Analysts
... Diagnostics), and Others; Services - Clinical Biomarker Services, Specimen Preparation, and Bioinformatics and Others (miRNA Analysis and Others). The total market is also analyzed by the following Application Areas: Biomarker Discovery, Clinical Drug Development, and ...  |  more...
$4,800.00
US Biochips Market
8/1/2011 | published by: Taiyou Research
... and its related products is foreseen to rise by approximately ten percent by 2015. Profits will definitely be a consequence of major contributions by microarray automation and cost efficiency of products. Though the industry’s future ...  |  more...
$400.00
Novel Approaches to Developing Predictive Diagnostics
7/1/2011 | published by: Decision Resources
... spent annually on drug R&D, but more than 90% of R&D projects fail to yield marketable drugs because of safety and efficacy issues. Biomarkers and diagnostics offer the tools necessary to predict drug failures before ...  |  more...
$4,600.00
Biomarkers: Technological and Commercial Outlook 2011-2021
6/22/2011 | published by: Visiongain
... help in your decisions. You will find revenue forecasts to 2021 at overall world, submarket and national levels. What technologies and applications will increase the use of biomarkers? What effects will changes and regulations have? ...  |  more...
$2,331.00
Germany Nephrology Biomarkers - A Market Snapshot
6/10/2011 | published by: GlobalData
... applications of different biomarkers in the diagnosis of renal failure and monitoring of patients post transplant. The report analyses the market size and volume of key biomarkers such as Serum Creatinine (SCr) and Neutrophil Gelatinase ...  |  more...
$500.00
Tumor Markers: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers
6/1/2011 | published by: Venture Planning Group
... of emerging diagnostic technologies Forecasts sales of major tumor markers by country and market segment Profiles leading market players and potential entrants Suggests alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is ...  |  more...
$28,500.00
Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases
6/1/2011 | published by: Decision Resources
... patients who will respond satisfactorily to targeted therapies and to stratify patients according to disease severity so the most appropriate treatment can be delivered to the right patients. Will pharmaceutical and biotechnology companies invest in ...  |  more...
$4,600.00
Advances in Drug-Diagnostic Co-Development
5/5/2011 | published by: Business Insights
... validation are assessed and case studies given of regulatory approvals of drugs and companion tests. Strategies for drug-diagnostic co-development are evaluated. Features and benefits Understand the current regulatory environment for both diagnostics and drugs within ...  |  more...
$3,835.00
< prev 1  2  3  4  5  next >